Toward responsible clinical n-of-1 strategies for rare diseases

Drug Discov Today. 2023 Oct;28(10):103688. doi: 10.1016/j.drudis.2023.103688. Epub 2023 Jun 24.

Abstract

N-of-1 strategies can provide high-quality evidence of treatment efficacy at the individual level and optimize evidence-based selection of off-label treatments for patients with rare diseases. Given their design characteristics, n-of-1 strategies are considered to lay at the intersection between medical research and clinical care. Therefore, whether n-of-1 strategies should be governed by research or care regulations remains a debated issue. Here, we delineate differences between medical research and optimized clinical care, and distinguish the regulations which apply to either. We also set standards for responsible optimized clinical n-of-1 strategies with (off-label) treatments for rare diseases. Implementing clinical n-of-1 strategies as defined here could aid in optimized treatment selection for such diseases.

Keywords: clinical care; learning healthcare systems; methodology; personalized medicine; rare diseases; single patient trial.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Patient Selection
  • Rare Diseases* / drug therapy
  • Treatment Outcome